...
首页> 外文期刊>Antimicrobial agents and chemotherapy. >Thioridazine pharmacokinetic-pharmacodynamic parameters 'wobble' during treatment of tuberculosis: A theoretical basis for shorter-duration curative monotherapy with congeners
【24h】

Thioridazine pharmacokinetic-pharmacodynamic parameters 'wobble' during treatment of tuberculosis: A theoretical basis for shorter-duration curative monotherapy with congeners

机译:噻嗪类药物在肺结核治疗期间的药代动力学-药效学参数“摇摆”:短期使用同类药物治疗单一疗法的理论基础

获取原文
获取原文并翻译 | 示例
           

摘要

Phenothiazines are being repurposed for treatment of tuberculosis. We examined time-kill curves of thioridazine and first-line drugs against log-growth-phase and semidormant bacilli under acidic conditions and nonreplicating persistent Mycobacterium tuberculosis. While both the potency and the efficacy of first-line drugs declined dramatically as M. tuberculosis replication rates decreased, those of thioridazine improved. The mutation prevalence to 3 times the thioridazine MIC was 1 × 10-11, better than for ≥2 first-line drugs combined. Hollow fiber system studies revealed that the relationship between sterilizing effect and pharmacodynamic indices (PDI) was characterized by an r2 of 0.88 for peak/MIC, an r2 of 0.47 for the area under the concentration-time curve (AUC) to MIC, and an r2 of 0.14 for the cumulative percentage of a 24-h period that the drug concentration exceeds the MIC under steady-state pharmacokinetic conditions (%TMIC) at the end of the first week. However, the PDI linked to effect "wobbled" as the duration of therapy increased, so that by the fourth week the r2 was 0.88 for AUC/MIC, 0.78 for %T MIC, and 0.72 for peak/MIC. This "wobble" has implications on general pharmacokinetic/pharmacodynamic theory, whereby efficacy is linked to only one of the three PDIs in deterministic models. The potency changed 8.9-fold from the first to the fourth weeks. The non-protein-bound AUC/MIC associated with maximal kill at the end of therapy was 50.53 (protein binding=99.5%). This thioridazine exposure was calculated to extinguish all three M. tuberculosis metabolic populations in human lungs in only 42.9 days of monotherapy. However, this concentration exceeds the 2- to 8-mg/liter thioridazine concentration in serum known to be lethal to humans. Therefore, the way forward for phenothiazine monotherapy that also reduces therapy duration is via synthesis of less toxic congeners.
机译:吩噻嗪正被重新用于治疗结核病。我们研究了在酸性条件下和非复制型持续性结核分枝杆菌对付对数生长期和半休眠杆菌的硫代哒嗪和一线药物的时间杀灭曲线。随着结核分枝杆菌复制率的降低,一线药物的效价和功效都急剧下降,而硫代哒嗪的药物效价和功效却有所改善。硫代哒嗪MIC的3倍突变发生率<1×10-11,优于≥2种一线药物的总和。中空纤维系统研究表明,灭菌效果与药效指数(PDI)之间的关系的特征是峰/ MIC的r2为0.88,在MIC的浓度-时间曲线(AUC)下面积的r2为0.47,并且在第一周结束时,在稳态药代动力学条件下(%TMIC),药物浓度超过MIC的24小时内累计百分比的r2为0.14。但是,随着治疗时间的延长,PDI与效果“摇摆”有关,因此到第四周,AUC / MIC的r2为0.88,%T MIC的r2为0.78,峰值/ MIC的r2为0.72。这种“摇摆”对一般的药代动力学/药效学理论有影响,在该理论中,功效仅与确定性模型中的三个PDI之一相关。从第一周到第四周,效价改变了8.9倍。在治疗结束时,与最大杀伤力相关的非蛋白结合的AUC / MIC为50.53(蛋白结合率为99.5%)。据计算,仅在单药治疗的42.9天内,这种硫代达嗪的暴露就可以消灭人肺中所有三个结核分枝杆菌的代谢种群。然而,该浓度超过了已知对人致命的血清中2至8毫克/升的硫代哒嗪浓度。因此,吩噻嗪单药治疗还可以缩短治疗时间的方法是合成毒性较小的同类药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号